AI-driven solutions are only as good as the data used to train them. From accurate testing numbers to comprehensive infection rates, data are essential to understanding COVID-19 and crafting national policy, including the allocation of limited health-resources. Yet high volume, high quality data isn’t readily available everywhere, and the gap between what is needed and what is available can be substantial, especially in low resource settings.
Understanding the importance of data for informing decision-making, this webinar will bring together data scientists and policy experts to discuss opportunities and challenges to meet this urgent need. Panelists will reflect on novel approaches for acquiring data; discuss the ethical and regulatory implications of their use and dive into recommendations on how to overcome ongoing barriers to data collection during COVID-19.
Moderated by Bruno Villetelle, Head of Data and Digital Global Drug Development at Novartis.
Bruno joined Novartis in April 2019 and leads the Data and Digital function for the company’s Global Drug Development (GDD) organization. He drives GDD’s data and digital vision, strategy and governance, and is focused on embedding data science and digital technologies to enhance asset development. Bruno has more than 30 years of experience spearheading digital and technology led innovation and new business model creation in the pharmaceutical, consumer health, and service industries. Prior to joining Novartis, he worked for Takeda Pharmaceutical Company Limited, a global top 10 pharmaceutical company, where he was Chief Digital Officer and oversaw more than 40 digital lighthouse programs. He also led the development of a portfolio of digital health companies offering game-changing digital solutions for patients and drug development.
Bruno has a Master of Science degree in Industrial Organization & Methodology and a Master of Science in Business Systems Management from the University of Lyon, France.